Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
2024 · Journal of Hematology & Oncology · 39 citations
https://doi.org/10.1186/s13045-024-01555-4
O
Omar Castañeda Puglianini
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
21
Papers
107
Citations
4
h-index
3
i10-index
Omar Castañeda Puglianini is an academic researcher from Moffitt Cancer Center. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & CAR-T cell therapy research & Biosimilars and Bioanalytical Methods. The author has an h-index of 4, co-authored 18 publications.
Papers by this author
worksCARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies
2024 · Seminars in Hematology · 4 citations
https://doi.org/10.1053/j.seminhematol.2024.08.005
P-123 Patient Preferences for use of CAR-T therapy as an Early Line Treatment in Multiple Myeloma
2024 · Clinical Lymphoma Myeloma & Leukemia · 1 citations
https://doi.org/10.1016/s2152-2650(24)02026-3
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
2025 · Blood Advances · 1 citations
https://doi.org/10.1182/bloodadvances.2025016131
Development and Validation of the SCOPE-MM Score: A Pre-Apheresis Risk Model Predicting Response and Toxicity in RRMM Patients Receiving BCMA-Directed CAR-T Therapy
2025 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(25)03407-x
Rapid Peak CAR-T Expansion is Associated with Delayed Neurotoxicity Following Ciltacabtagene Autoleucel in Multiple Myeloma
2025 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(25)03409-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat